EP4164689A4 - Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1 - Google Patents

Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1 Download PDF

Info

Publication number
EP4164689A4
EP4164689A4 EP21821720.6A EP21821720A EP4164689A4 EP 4164689 A4 EP4164689 A4 EP 4164689A4 EP 21821720 A EP21821720 A EP 21821720A EP 4164689 A4 EP4164689 A4 EP 4164689A4
Authority
EP
European Patent Office
Prior art keywords
diabetes
compositions
methods
preventing type
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21821720.6A
Other languages
English (en)
French (fr)
Other versions
EP4164689A2 (de
Inventor
Francisco Leon
Kevan C. Herold
Sarah Alice LONG
Peter S. Linsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Virginia Mason Medical Center
Provention Bio Inc
Original Assignee
Yale University
Virginia Mason Medical Center
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW110102871A external-priority patent/TWI889747B/zh
Application filed by Yale University, Virginia Mason Medical Center, Provention Bio Inc filed Critical Yale University
Priority claimed from PCT/US2021/037039 external-priority patent/WO2021252917A2/en
Publication of EP4164689A2 publication Critical patent/EP4164689A2/de
Publication of EP4164689A4 publication Critical patent/EP4164689A4/de
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517CD8
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
EP21821720.6A 2020-06-11 2021-06-11 Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1 Pending EP4164689A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063037968P 2020-06-11 2020-06-11
TW110102871A TWI889747B (zh) 2020-06-11 2021-01-26 用於預防第1型糖尿病的方法及組成物
US202163192242P 2021-05-24 2021-05-24
PCT/US2021/037039 WO2021252917A2 (en) 2020-06-11 2021-06-11 Methods and compositions for preventing type 1 diabetes

Publications (2)

Publication Number Publication Date
EP4164689A2 EP4164689A2 (de) 2023-04-19
EP4164689A4 true EP4164689A4 (de) 2024-07-24

Family

ID=85557394

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21821720.6A Pending EP4164689A4 (de) 2020-06-11 2021-06-11 Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1

Country Status (1)

Country Link
EP (1) EP4164689A4 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) * 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) * 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KEVAN C. HEROLD ET AL: "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 381, no. 7, 15 August 2019 (2019-08-15), US, pages 603 - 613, XP055760445, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1902226 *

Also Published As

Publication number Publication date
EP4164689A2 (de) 2023-04-19

Similar Documents

Publication Publication Date Title
EP4247376A4 (de) Verbindungen, zusammensetzungen und verfahren
AU2023275531B2 (en) Methods and compositions for preventing or delaying type 1 diabetes
EP4370110A4 (de) Verbindungen, zusammensetzungen und verfahren
EP4025556A4 (de) Lipidverbindung und ihre zusammensetzung
HK40095886A (en) Methods and compositions for preventing type 1 diabetes
EP4164689A4 (de) Verfahren und zusammensetzungen zur prävention von diabetes vom typ 1
EP4054558A4 (de) Verfahren und zusammensetzungen zur behandlung von typ-2-diabetes
HK40122704A (en) Methods and compositions for preventing or delaying type 1 diabetes
AU2021900857A0 (en) Anti-Mollusc Composition (4)
AU2020900932A0 (en) Anti-Mollusc Composition (3)
CA3286507A1 (en) Compositions and methods for agri-inputs and uses thereof
HK40089082A (en) Methods and compositions for the treatment and prevention of type 1 diabetes
AU2024370508A1 (en) Compounds, compositions and methods thereof
CA3306739A1 (en) Compounds, compositions and methods thereof
CA3288518A1 (en) Modified trems, compositions, and related methods thereof
AU2022900746A0 (en) Anti-Mollusc Composition (5)
CA3308856A1 (en) Compounds, compositions, and methods
CA3299170A1 (en) Compounds, compositions, and methods
CA3288852A1 (en) Compounds, compositions, and methods
CA3277032A1 (en) Compounds, compositions, and methods
CA3270199A1 (en) Compounds, compositions and methods
HK40110347A (en) Stabilized apilimod compositions and uses thereof
HK40122617A (en) Compounds, compositions, and methods
CA3295097A1 (en) Compositions and uses thereof
CA3295099A1 (en) Compositions and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230109

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095886

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20240624

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20240619BHEP

Ipc: A61P 3/10 20060101ALI20240619BHEP

Ipc: A61K 39/395 20060101AFI20240619BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250508